Provided by Tiger Trade Technology Pte. Ltd.

IDEAYA Biosciences

42.48
+2.446.09%
Post-market: 42.480.00000.00%16:30 EDT
Volume:1.02M
Turnover:42.97M
Market Cap:4.09B
PE:-21.72
High:42.68
Open:40.88
Low:40.06
Close:40.04
52wk High:42.68
52wk Low:23.23
Shares:96.27M
Float Shares:94.37M
Volume Ratio:1.06
T/O Rate:1.08%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9561
EPS(LYR):-1.2849
ROE:-16.22%
ROA:-11.54%
PB:3.41
PE(LYR):-33.06

Loading ...

IDEAYA Biosciences Announces First-Patient-in for Phase 1 Trial of Ide574, a Potential First-in Class Dual Inhibitor of Kat6/7 to Target Multiple Solid Tumor Indications, Including Breast, Prostate, Crc, and Lung Cancer

THOMSON REUTERS
·
Apr 06

Should IDEAYA’s DLL3 Combo Trial and Early IDE849 Signals Prompt a Rethink From IDYA Investors?

Simply Wall St.
·
Apr 04

IDEAYA Biosciences Price Target Maintained With a $52.00/Share by Wedbush

Dow Jones
·
Mar 31

Analysts Offer Insights on Healthcare Companies: PepGen Inc. (PEPG) and IDEAYA Biosciences (IDYA)

TIPRANKS
·
Mar 31

BUZZ-U.S. STOCKS ON THE MOVE-Agnico Eagle Mines, ProPetro, Kezar

Reuters
·
Mar 30

BUZZ-U.S. STOCKS ON THE MOVE-Insmed, United Therapeutics, CrowdStrike

Reuters
·
Mar 30

BRIEF-Ideaya Biosciences Announces First-Patient-In For Phase 1 Combination Study Of Ide849, Dll3 Top1 Adc, And Ide161, Parg Inhibitor, In Dll3 Upregulated Solid Tumor Indications, Including Sclc, Nets, Necs, And Melanoma

Reuters
·
Mar 30

BUZZ-U.S. STOCKS ON THE MOVE-Energy shares, miners, Sysco

Reuters
·
Mar 30

BUZZ-Ideaya rises as it starts early-stage trial of combination of cancer drugs

Reuters
·
Mar 30

IDEAYA starts Phase 1 trial of IDE849-IDE161 combo in DLL3 solid tumors

Reuters
·
Mar 30

IDEAYA Biosciences Announces First-Patient-in for Phase 1 Combination Study of Ide849, Dll3 Top1 ADC, and Ide161, Parg Inhibitor, in Dll3 Upregulated Solid Tumor Indications, Including Sclc, Nets, Necs, and Melanoma

THOMSON REUTERS
·
Mar 30

IDEAYA Biosciences Inc - Targets Clinical Data Update for Ide849 and Ide161 in H2 2026

THOMSON REUTERS
·
Mar 30

Analysts’ Top Healthcare Picks: Tarsus Pharmaceuticals (TARS), IDEAYA Biosciences (IDYA)

TIPRANKS
·
Mar 28

IDEAYA Biosciences grants 49,000 inducement stock options; exercise price set at $32.09

Reuters
·
Mar 27

IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Mar 27

Assessing IDEAYA Biosciences (IDYA) Valuation After Recent Share Price Weakness

Simply Wall St.
·
Mar 24

Ideaya Biosciences updates guidance related to timing of Phase 2/3 data release

TIPRANKS
·
Mar 23

Ideaya Biosciences falls -6.0%

TIPRANKS
·
Mar 23

Analysts’ Top Healthcare Picks: Madrigal Pharmaceuticals (MDGL), IDEAYA Biosciences (IDYA)

TIPRANKS
·
Mar 23

J.P. Morgan Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)

TIPRANKS
·
Mar 23